CA-HEPTAGON
22.2.2016 08:02:35 CET | Business Wire | Press release
Heptagon (www.hptg.com ), an industry leader in 3D imaging, sensing and illumination solutions for the Internet of Things (IoT) and Smart Devices, today announced it has shipped over 2 billion units to customers. The company, which is headquartered in Singapore, recently opened a new factory with expanded capacity to ship 1 billion units per year. Heptagon serves some of the largest makers of mobile and IoT products in the world. Its success is attributed to relentless dedication to innovation, consistently delivering top-quality, high-performance products to market quickly, and leading edge wafer level manufacturing capabilities that meet the needs of the fast-paced and rapidly-evolving IoT and smart device industries.
"We are delighted to announce this latest milestone in our rapid growth and see this as ongoing acceptance by the market of our innovative, world-class products," says Christian Tang-Jespersen, CEO and President of Heptagon. "We look forward to continuing our strong growth and reaching our next billion units shipped milestone.”
"We are well positioned to pursue new market opportunities with the expansion of our fab in Woodlands, Singapore and the opening of our new factory in Ang Mo Kio, Singapore," says S.C. Leong, Heptagon’s Chief Operating Officer. “We remain committed to uncompromising quality and our proven ability to move quickly from white board to shipping 100s of millions of units."
In addition to opening the new factory in Singapore, Heptagon has expanded its sales, marketing and engineering presence in Silicon Valley as a result of strong customer interest in the company’s product and miniaturization, integration, optical and electrical design expertise. Heptagon’s newly created Silicon Valley Labs and Executive Briefing Center showcase the latest interface and sensing technologies while providing convenient access for the innovators and decision makers in Silicon Valley.
With in-depth and unique knowledge and expertise in all major 3D imaging and sensing technologies including stereo vision, structured light and Time-of-Flight (ToF), Heptagon is ready to address a fast-growing market segment of 3D. The company’s products continue to push the boundaries of what is possible in 3D today. As a pioneer of ToF imaging, it recently introduced the industry’s first multipoint 3D ranging sensor for mobile application. Further, its proprietary technologies like adaptive stereo enables indoor and outdoor imaging in a single solution and create a unique platform for 3D capturing where the adaptive illumination technology powers interference free multi-user applications as needed in collaborative augmented reality, automotive cockpits and digital signage.
The need to integrate heterogeneous technologies in miniaturized packages is rapidly becoming the enabler of next generation products in mobile, wearables and IoT. Over 20 years of innovation in technology, manufacturing and operations, as well as a rigorous supply chain management form the foundation for Heptagon’s differentiation and uniquely positions the company to innovate and rapidly bring world-class products to market.
About Heptagon
Heptagon (www.hptg.com ) provides complete 3D/imaging, illumination and optical sensing solutions for smart devices and the internet of things. With over 2 billion units shipped and 20 years of industry firsts in miniaturizing and integrating complex hardware and software systems, Heptagon has industry leading technology and services to enhance our customer’s competitiveness. Backed by world-class investors, Heptagon is a global company with research and development, sales and customer services teams located in Singapore, Zurich Switzerland, in Silicon Valley USA, and Shenzhen China.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160221005200/en/
Contact:
Heptagon
Scott Filler +1 408-329-8920
pr@hptg.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom